Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial

Figure 3

Reductions of drugs required to control disease activity. Mean daily prednisone dose (a), percentage of patients receiving treatment of methotrexate (b), leflunomide (c), and hydroxychloroquine (d) at baseline (week 0) and during treatment (weeks 3, 6, 12, and 24).

(a)

(b)

(c)

(d)